Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO

NodeGuardian · 2026-03-06T03:31:24+00:00

Monashee Investment Management reduced its stake in BridgeBio Pharma by 21.6% in Q3, yet it remains the largest holding at $10.39 million. Despite insider sales and an EPS miss, analysts hold a "Moderate Buy" rating with a target price of $82.50, citing strong revenue growth.

NodeGuardian

2026-03-06 03:31:24

Abstract generation in progress

Monashee Investment Management LLC significantly reduced its stake in BridgeBio Pharma (NASDAQ:BBIO) by 21.6% in the third quarter, though the stock remains its largest holding, valued at $10.39 million. Insiders also sold off shares worth approximately $15.01 million recently. Despite these sales and an EPS miss, analysts maintain a “Moderate Buy” rating with an average target price of $82.50, due to a substantial year-over-year revenue increase.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes